<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03719755</url>
  </required_header>
  <id_info>
    <org_study_id>17-000176</org_study_id>
    <nct_id>NCT03719755</nct_id>
  </id_info>
  <brief_title>Urinary Tract Infections Rates Using 50% Dextrose Plus Washout Versus Normal Saline as Cystoscopy Fluid</brief_title>
  <official_title>Comparison of Urinary Tract Infections Rates Using 50% Dextrose Plus Washout Versus Normal Saline as Cystoscopy Fluid: a Prospective Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Our study will compare the rates of postoperative urinary tract infections (UTI) between
      patients who undergo cystoscopy using 50% dextrose injection plus bladder washout versus
      normal saline after hysterectomy for benign indications. Primary outcome will be rates of
      urinary tract infections at 6-9 days post-operatively. This will be defined as a urine
      culture yielding greater than 100,000 gram-negative colony-forming units per milliliter.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This will be a prospective cohort study of the rate of UTIs after cystoscopic distention
      media of normal saline with maximum injection of 40 cc of 50% dextrose plus 300 cc of normal
      saline washout versus normal saline after hysterectomy for benign indications.

      A pre-operative urine culture will be obtained via mid-stream clean catch prior to
      administration of routine pre-operative prophylactic antibiotics.

      At 6-9 days post-operatively, a repeat urine culture will be obtained via mid-stream clean
      catch. Appropriate treatment will be administered if the urine culture is positive.Primary
      outcome will be rates of urinary tract infections at 6-9 days post-operatively. This will be
      defined as a urine culture yielding greater than 100,000 gram-negative colony-forming units
      per milliliter.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 1, 2018</start_date>
  <completion_date type="Anticipated">September 9, 2020</completion_date>
  <primary_completion_date type="Anticipated">September 9, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>Subjects are blinded to distention media</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>rates of urinary tract infections at 6-9 days post-operative</measure>
    <time_frame>6-9 days post-operative</time_frame>
    <description>be rates of urinary tract infections at 6-9 days post-operatively. This will be defined as a urine culture yielding greater than 100,000 gram-negative colony-forming units per milliliter</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">140</enrollment>
  <condition>Hysterectomy</condition>
  <arm_group>
    <arm_group_label>50% dextrose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Cystoscopic distention of 40 cc of 50% dextrose plus 300 cc of normal saline washout</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Normal Saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Cystoscopic distention media of normal saline.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>50% dextrose</intervention_name>
    <description>maximum injection of 40 cc of 50% dextrose plus 300 cc of normal saline washout versus normal saline after hysterectomy for benign indications.</description>
    <arm_group_label>50% dextrose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Normal Saline</intervention_name>
    <description>Cystoscopic distention media of normal saline</description>
    <arm_group_label>Normal Saline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Preoperative scheduling CPT codes for hysterectomy

        Exclusion Criteria:

          -  Discharged home with indwelling foley catheter

          -  Indwelling foley catheter &gt; 24 hours

          -  Ureteral injury

          -  Chronic immunosuppression

          -  History of diabetes

          -  Recurrent UTIs (≥2 infections in six months or ≥3 infections in one year)

          -  Reported Chronic Kidney Disease

          -  Renal anomalies
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>hysterectomy for all indications</gender_description>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeffrey Cornella, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Saran Vauughn</last_name>
    <phone>480-342-6487</phone>
    <email>vaughn.saran@mayo.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Deb Ryan</last_name>
    <phone>480-342-1208</phone>
    <email>ryan.debra29@mayo.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85259</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heather Crowe</last_name>
      <phone>480-342-3987</phone>
      <email>Crowe.Heather1@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Jeffrey Cornella, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mayo.edu/research/clinical-trials</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>October 19, 2018</study_first_submitted>
  <study_first_submitted_qc>October 23, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 25, 2018</study_first_posted>
  <last_update_submitted>October 17, 2019</last_update_submitted>
  <last_update_submitted_qc>October 17, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 21, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Jeffrey L. Cornella</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Tract Infections</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

